Literature DB >> 3674094

Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization.

G B Appel1, D J Cohen, C L Pirani, J I Meltzer, D Estes.   

Abstract

The long-term course of 56 patients with systemic lupus erythematosus who had precisely defined renal histology and carefully assessed clinical status at the time of their initial renal biopsy prior to 1976 was evaluated and analyzed by life-table analysis. The average length of follow-up has now been greater than 10 years since initial biopsy. Patients with mesangial lesions (World Health Organization [WHO] classes IIA and IIB) had a more favorable renal and patient survival at five and 10 years than did patients in the other WHO classes (III, IV, and V). Individual renal histologic features of activity and chronicity when combined into an activity index and a chronicity index did not significantly predict renal survival in this population, nor did the presence of hypertension or renal dysfunction at the time of the initial renal biopsy significantly influence renal or patient survival. Patients with the nephrotic syndrome at initial biopsy had a poorer renal survival than did patients without the nephrotic syndrome. However, patients who experienced a remission of the nephrotic syndrome fared better in terms of both renal and patient survival than did those patients without a remission. By life-table analysis, patient survival was significantly better for patients in whom biopsy was performed after 1973 than for those in whom biopsy was performed prior to that time despite similar clinical features and WHO histology in each group interval. Our data suggest that improved survival for patients in recent studies may relate to better supportive care and more selective use of immunosuppressive therapy in patients with milder forms of lupus nephritis.

Entities:  

Mesh:

Year:  1987        PMID: 3674094     DOI: 10.1016/0002-9343(87)90645-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  58 in total

1.  Systemic lupus erythematosus. III. Observations on clinical renal involvement and follow up of renal function: Dutch experience with 110 patients studied prospectively.

Authors:  J C Nossent; W Bronsveld; A J Swaak
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

2.  Renal haemodynamic characteristics in patients with lupus nephritis.

Authors:  M Nakano; M Ueno; H Hasegawa; T Watanabe; T Kuroda; S Ito; M Arakawa
Journal:  Ann Rheum Dis       Date:  1998-04       Impact factor: 19.103

3.  Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis.

Authors:  Oliver Lenz; Alessia Fornoni; Gabriel Contreras
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Histopathological indicators of disease outcome in class IV lupus nephritis: a revisit of various indices.

Authors:  Manish Rathi; Krishan Lal Gupta; Kusum Joshi; Pramod K Gupta; Aman Sharma; Harbir Singh Kohli; Vivekanand Jha; Vinay Sakhuja
Journal:  Rheumatol Int       Date:  2015-03-11       Impact factor: 2.631

5.  Is serum uric acid a predictor of long-term renal outcome in lupus nephritis?

Authors:  Michelle Remião Ugolini-Lopes; Samara S Gavinier; Elaine Leon; Vilma Trindade Viana; Eduardo Ferreira Borba; Eloisa Bonfá
Journal:  Clin Rheumatol       Date:  2019-06-02       Impact factor: 2.980

6.  Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006.

Authors:  Karen H Costenbader; Amrita Desai; Graciela S Alarcón; Linda T Hiraki; Tamara Shaykevich; M Alan Brookhart; Elena Massarotti; Bing Lu; Daniel H Solomon; Wolfgang C Winkelmayer
Journal:  Arthritis Rheum       Date:  2011-06

7.  Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population.

Authors:  Juan Manuel Mejía-Vilet; Bertha M Córdova-Sánchez; Norma O Uribe-Uribe; Ricardo Correa-Rotter
Journal:  Clin Rheumatol       Date:  2016-07-30       Impact factor: 2.980

8.  Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.

Authors:  Howard A Austin; Gabor G Illei; Michelle J Braun; James E Balow
Journal:  J Am Soc Nephrol       Date:  2009-03-18       Impact factor: 10.121

Review 9.  The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis.

Authors:  Marcus R Clark; Kimberly Trotter; Anthony Chang
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

10.  Outcome of lupus nephritis in Iranian children: prognostic significance of certain features.

Authors:  Neamatollah Ataei; Manijeh Haydarpour; Abbas Madani; Seyed Taher Esfahani; Niloufar Hajizadeh; Mohammad Hasan Moradinejad; Taghi Gholmohammadi; Shahriar Arbabi; Marzieh Haddadi
Journal:  Pediatr Nephrol       Date:  2008-02-13       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.